एकालाब्रुटिनिब और एसोमेप्राज़ोल का इंटरैक्शन

• Gastric Acid Reducing Agents: Avoid co-administration with proton pump inhibitors (PPIs).

Proton pump inhibitors Avoid co-administration.

Gastric Acid Reducing Agents Clinical Effect • Co-administration of CALQUENCE with a proton pump inhibitor, H2-receptor antagonist, or antacid may decrease acalabrutinib plasma concentrations [see Clinical Pharmacology (12.3) ] .

• If treatment with a gastric acid reducing agent is required, consider using a H2‑receptor antagonist (e.g., ranitidine or famotidine) or an antacid (e.g., calcium carbonate).

Due to the long-lasting effect of proton pump inhibitors, separation of doses may not eliminate the interaction with CALQUENCE.